All News

Top officials at EMA push the boat out on drug-pricing views.

Click the title above to open the Pharmaceutical Executive June 2016 issue in an interactive PDF format.

Policymakers seek to limit prescribing while also encouraging innovative R&D.

Click the title above to open the Pharmaceutical Executive May 2016 issue in an interactive PDF format.

How the DIA, a key industry NGO, is repositioning itself as the go-to place for the independent knowledge-driven insights that drive decisions in a business with no boundaries. One world. One table. Open seating.

Altruism and self-interest are at the heart of European thinking on neglected diseases.

The practice’s emerging-if improbable-cost-saving potential.

Click the title above to open the Pharmaceutical Executive April 2016 issue in an interactive PDF format.

Europe’s contrasting views on rare disease drugs - one bashing pricing abuses, the other extolling their public health virtues - could ultimately leave these products out in the cold.

Click the title above to open the Pharmaceutical Executive March 2016 issue in an interactive PDF format.

As US pharma continues to ponder its “winter of discontent”, the question that leaders of industry have to be asking themselves is, “How did things get this bad?” Tom Norton reports.